DYVERTO AG GETS A COMBINED “SEED” FUNDING OF NEARLY 1 MILLION EUROS for the development of a novel treatment for small abdominal aortic aneurysms.
January 27, 2023
Dyverto AG, an innovative start-up operating in the vascular sector created by CVLab, announces the entry into the share capital of Davide Bianchi and Nocturnal Labs SpA.
The “seed” investment is intended for the development of a device aimed at stopping and potentially reversing the progression of arterial aneurysms. The funds will be used to complete an in-depth proof of concept for an abdominal application, continue the development of the device and its delivery system and strengthen the company’s IP position.
Built on an idea coming from Prof. Alessandro Bortone, Dyverto’s concept already brings to bear a robust body of preliminary data developed with top research institutions including the “Politecnico di Torino” (CFD), the “Department of Fisica Medica” of the Policlinico Sant’Orsola in Bologna (in vitro modeling and testing) and the “CRABBC” (Centro di Ricerche ed Applicazioni Biotecnologiche in Chirurgia Cardiovascolare) for the animal work.
According to one of the Clinical Advisors involved in the preliminary evaluations of the technology, “Dyverto could be a game-changing approach to intervene tackling the progression of the disease instead of simply focusing on mechanically addressing its consequences”.
“We strongly believe in Dyverto’s potential. Through its technology platform we see the opportunity to explore a number of hi-value applications across the vascular field” stated both Luigi Colombo, CEO of Nocturnal Labs and Davide Bianchi”.
ABOUT Dyverto: Dyverto is a med-tech startup recently spun-off by Cardiovascular Lab (CVLab) the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. Dyverto focuses on the development of novel approaches for the rehabilitation of arteries affected by aneurysms or other life-threatening diseases.
ABOUT Cardiovascular Lab (CVLab): Cardiovascular Lab is the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. CVLAb takes the most promising ones through patenting, prototyping and proof-of-concept, all the way to spinning-off a new company and seeking venture capital funding.
ABOUT Nocturnal Labs: Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health. The Nocturnal labs team’s combination of research, development, clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry which can provide benefit and value for patients, doctors and healthcare systems, and reward shareholders with a sound and ethical profit.
ABOUT Davide Bianchi: Davide is an investor/entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix. More recently Davide was part of the team orchestrating the creation of Corcym – where he serves as Chairman of the Board – the company that completed the carve-out of the Sorin heart valves business of Livanova.
DYVERTO AG GETS A COMBINED “SEED” FUNDING OF NEARLY 1 MILLION EUROS for the development of a novel treatment for small abdominal aortic aneurysms.
January 27, 2023
Dyverto AG, an innovative start-up operating in the vascular sector created by CVLab, announces the entry into the share capital of Davide Bianchi and Nocturnal Labs SpA.
The “seed” investment is intended for the development of a device aimed at stopping and potentially reversing the progression of arterial aneurysms. The funds will be used to complete an in-depth proof of concept for an abdominal application, continue the development of the device and its delivery system and strengthen the company’s IP position.
Built on an idea coming from Prof. Alessandro Bortone, Dyverto’s concept already brings to bear a robust body of preliminary data developed with top research institutions including the “Politecnico di Torino” (CFD), the “Department of Fisica Medica” of the Policlinico Sant’Orsola in Bologna (in vitro modeling and testing) and the “CRABBC” (Centro di Ricerche ed Applicazioni Biotecnologiche in Chirurgia Cardiovascolare) for the animal work.
According to one of the Clinical Advisors involved in the preliminary evaluations of the technology, “Dyverto could be a game-changing approach to intervene tackling the progression of the disease instead of simply focusing on mechanically addressing its consequences”.
“We strongly believe in Dyverto’s potential. Through its technology platform we see the opportunity to explore a number of hi-value applications across the vascular field” stated both Luigi Colombo, CEO of Nocturnal Labs and Davide Bianchi”.
ABOUT Dyverto: Dyverto is a med-tech startup recently spun-off by Cardiovascular Lab (CVLab) the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. Dyverto focuses on the development of novel approaches for the rehabilitation of arteries affected by aneurysms or other life-threatening diseases.
ABOUT Cardiovascular Lab (CVLab): Cardiovascular Lab is the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. CVLAb takes the most promising ones through patenting, prototyping and proof-of-concept, all the way to spinning-off a new company and seeking venture capital funding.
ABOUT Nocturnal Labs: Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health. The Nocturnal labs team’s combination of research, development, clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry which can provide benefit and value for patients, doctors and healthcare systems, and reward shareholders with a sound and ethical profit.
ABOUT Davide Bianchi: Davide is an investor/entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix. More recently Davide was part of the team orchestrating the creation of Corcym – where he serves as Chairman of the Board – the company that completed the carve-out of the Sorin heart valves business of Livanova.
DYVERTO AG GETS A COMBINED “SEED” FUNDING OF NEARLY 1 MILLION EUROS for the development of a novel treatment for small abdominal aortic aneurysms.
January 27, 2023
Dyverto AG, an innovative start-up operating in the vascular sector created by CVLab, announces the entry into the share capital of Davide Bianchi and Nocturnal Labs SpA.
The “seed” investment is intended for the development of a device aimed at stopping and potentially reversing the progression of arterial aneurysms. The funds will be used to complete an in-depth proof of concept for an abdominal application, continue the development of the device and its delivery system and strengthen the company’s IP position.
Built on an idea coming from Prof. Alessandro Bortone, Dyverto’s concept already brings to bear a robust body of preliminary data developed with top research institutions including the “Politecnico di Torino” (CFD), the “Department of Fisica Medica” of the Policlinico Sant’Orsola in Bologna (in vitro modeling and testing) and the “CRABBC” (Centro di Ricerche ed Applicazioni Biotecnologiche in Chirurgia Cardiovascolare) for the animal work.
According to one of the Clinical Advisors involved in the preliminary evaluations of the technology, “Dyverto could be a game-changing approach to intervene tackling the progression of the disease instead of simply focusing on mechanically addressing its consequences”.
“We strongly believe in Dyverto’s potential. Through its technology platform we see the opportunity to explore a number of hi-value applications across the vascular field” stated both Luigi Colombo, CEO of Nocturnal Labs and Davide Bianchi”.
ABOUT Dyverto: Dyverto is a med-tech startup recently spun-off by Cardiovascular Lab (CVLab) the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. Dyverto focuses on the development of novel approaches for the rehabilitation of arteries affected by aneurysms or other life-threatening diseases.
ABOUT Cardiovascular Lab (CVLab): Cardiovascular Lab is the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. CVLAb takes the most promising ones through patenting, prototyping and proof-of-concept, all the way to spinning-off a new company and seeking venture capital funding.
ABOUT Nocturnal Labs: Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health. The Nocturnal labs team’s combination of research, development, clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry which can provide benefit and value for patients, doctors and healthcare systems, and reward shareholders with a sound and ethical profit.
ABOUT Davide Bianchi: Davide is an investor/entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix. More recently Davide was part of the team orchestrating the creation of Corcym – where he serves as Chairman of the Board – the company that completed the carve-out of the Sorin heart valves business of Livanova.
